- Tytuł:
- A survey across orbital lymphoma in Poland : multicenter retrospective study of polish lymphoma research group (PLRG)
- Autorzy:
-
Kalicińska, Elżbieta
Wróbel, Tomasz
Giza, Agnieszka
Balcerzak, Andrzej
Jabłonowska, Paula
Knopińska-Posłuszny, Wanda
Rybka, Justyna
Paszkiewicz-Kozik, Ewa
Wojnar, Jerzy
Giebel, Sebastian
Romejko-Jarosińska, Joanna
Spychałowicz, Wojciech
Zaucha, Jan Maciej
Zimowska-Curyło, Dagmara
Andrasiak, Iga - Opis:
- Objective: To investigate the prevalence of histopathological subtypes, the clinical stage at presentation and treatment modalities in Polish patients with orbital lymphoma (OL) and to determine prognostic outcomes. Methods:The retrospective study of 107 patients with OL treated in a 14-year period in Polish hematological centers. The analysis included histopathological subtype, disease clinical advancement, treatment modalities, progression-free survival (PFS), and overall survival (OS). Results: The median patient age was 60 years (range 51–71). Mucosa-associated lymphoid tissue (MALT) lymphoma accounted for slightly more than half of all cases of orbital lymphoma (51%). The second most common subtype was diffuse large B-cell lymphoma (DLBCL) (29%). Primary orbital lymphoma was diagnosed in 48% of all patients. According to the Ann Arbor, localized stage IE of orbital lymphoma was diagnosed only in 39% of all patients. Systemic involvement was observed in more than half of all patients (52%). The median follow-up period was 30 months (range 0–160 months). Patients with non-MALT lymphoma had a significantly inferior PFS compared to patients with MALT lymphoma, (p = 0.047). Patients with primary orbital lymphoma had a superior PFS compared to patients with secondary orbital lymphoma [median PFS 104.5 months vs. 33.4 months], (p = 0.069). Younger patients with MALT lymphoma were characterized by superior PFS (median PFS not reached) compared to other studied subgroups of patients (older patients with MALT lymphoma, younger and older non-MALT lymphoma patients) with a median PFS of 30.5, 32.2, 32.6 months respectively (p = 0.039). Patients treated with chemotherapy alone had inferior PFS compared to patients treated with combined therapies (p = 0.034). The median PFS across patients who received chemotherapy alone was 23.7 months, whereas across other patients was 73.9 months.
- Dostawca treści:
- Repozytorium Uniwersytetu Jagiellońskiego
Artykuł